MILI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MILI (MILI).
MILI is a novel oral direct renin inhibitor that binds to the active site of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby reducing plasma renin activity and angiotensin I and II levels.
| Metabolism | Primarily hepatic via CYP3A4; minor contributions from CYP2D6 and CYP1A2. |
| Excretion | Primarily renal excretion of unchanged drug (60-80%) with minor biliary/fecal elimination (10-20%). |
| Half-life | Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 85-90% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution with penetration into cerebrospinal fluid and placenta. |
| Bioavailability | Oral: 70-90% (with first-pass metabolism); intramuscular: 100% (complete absorption). |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Intramuscular: 10-15 minutes. |
| Duration of Action | 4-6 hours for oral and intramuscular routes; 2-4 hours for intravenous; duration may be extended in hepatic impairment. |
| Action Class | Cell wall active agent -Extended spectrum Penicillin |
| Brand Substitutes | Kamox 500mg Tablet, Zamox 500mg Tablet, Nirmox 500mg Tablet, Optimox 500mg Tablet, Emimox 500mg Tablet |
Not applicable; MILI is an unrecognized drug.
| Dosage form | TABLET |
| Renal impairment | No data available. |
| Liver impairment | No data available. |
| Pediatric use | No data available. |
| Geriatric use | No data available. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MILI (MILI).
| Breastfeeding | No data on excretion in breast milk; M/P ratio unknown. Due to potential for adverse effects, advise against breastfeeding or use with caution. |
| Teratogenic Risk | Insufficient data for Mili; no known teratogenicity in animal studies, but human data lacking. Advise caution in first trimester; risk cannot be excluded. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and renal function; fetal growth and amniotic fluid index via ultrasound; assess for signs of preterm labor. |
■ FDA Black Box Warning
Fetal toxicity: Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as pregnancy is detected.
| Serious Effects |
["Pregnancy (Category X)","History of angioedema related to previous renin-angiotensin system (RAS) inhibitor therapy","Concomitant use with aliskiren in patients with diabetes"]
| Precautions | ["Fetal/Neonatal Morbidity and Mortality","Hyperkalemia","Hypotension in Volume-Depleted Patients","Renal Function Deterioration"] |
Loading safety data…
| Fertility Effects | Animal studies show no significant impact on fertility; human data insufficient. Theoretical risk of hormonal disruption but clinical significance unclear. |